Click here to close now.




















Welcome!

News Feed Item

Fatty Liver Disease Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Fatty Liver Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/617103/Fatty-Liver-Disease-Global-Clinical-Trials-Review-H2-2014.html

Fatty Liver Disease Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Fatty Liver Disease Global Clinical Trials Review, H2, 2014" provides data on the Fatty Liver Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fatty Liver Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Fatty Liver Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Fatty Liver Disease 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Fatty Liver Disease 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Fatty Liver Disease Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Fatty Liver Disease 33
Jul 30, 2014: Galectin Therapeutics Issues Statement on GR-MD-02 Development Program 33
Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 34
Clinical Trial Profiles 35
Clinical Trial Overview of Top Companies 35
Merck & Co., Inc. 35
Clinical Trial Overview of Merck & Co., Inc. 35
Galmed International Ltd. 36
Clinical Trial Overview of Galmed International Ltd. 36
F. Hoffmann-La Roche Ltd. 37
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 37
PharmaKing Co., Ltd. 38
Clinical Trial Overview of PharmaKing Co., Ltd. 38
Abbott Laboratories 39
Clinical Trial Overview of Abbott Laboratories 39
TCM Biotech International Corp 40
Clinical Trial Overview of TCM Biotech International Corp 40
Sanofi 41
Clinical Trial Overview of Sanofi 41
Phenex Pharmaceuticals AG 42
Clinical Trial Overview of Phenex Pharmaceuticals AG 42
GW Pharmaceuticals plc 43
Clinical Trial Overview of GW Pharmaceuticals plc 43
Genextra S.p.a. 44
Clinical Trial Overview of Genextra S.p.a. 44
Clinical Trial Overview of Top Institutes / Government 45
The National Institute of Diabetes and Digestive and Kidney Diseases 45
Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases 45
Tabriz University of Medical Sciences 46
Clinical Trial Overview of Tabriz University of Medical Sciences 46
Third Military Medical University 47
Clinical Trial Overview of Third Military Medical University 47
University of Michigan 48
Clinical Trial Overview of University of Michigan 48
Tehran University of Medical Sciences 49
Clinical Trial Overview of Tehran University of Medical Sciences 49
Washington University School of Medicine 50
Clinical Trial Overview of Washington University School of Medicine 50
University of California, San Diego 51
Clinical Trial Overview of University of California, San Diego 51
FUDAN University 52
Clinical Trial Overview of FUDAN University 52
Ahvaz Jundishapur University of Medical Sciences 53
Clinical Trial Overview of Ahvaz Jundishapur University of Medical Sciences 53
Bambino Gesu Hospital and Research Institute 54
Clinical Trial Overview of Bambino Gesu Hospital and Research Institute 54
Five Key Clinical Profiles 55
Appendix 82
Abbreviations 82
Definitions 82
Research Methodology 83
Secondary Research 84
About GlobalData 84
Contact Us 84
Disclaimer 84
Source 85

List of Tables
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Region, 2014* 7
Fatty Liver Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Fatty Liver Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Fatty Liver Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Fatty Liver Disease Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Fatty Liver Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Fatty Liver Disease Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, G7 Countries (%), 2014* 15
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, E7 Countries (%), 2014* 18
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Fatty Liver Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Fatty Liver Disease Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Fatty Liver Disease Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Fatty Liver Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Fatty Liver Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Fatty Liver Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Fatty Liver Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Fatty Liver Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 35
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Galmed International Ltd., 2014* 36
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 37
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by PharmaKing Co., Ltd., 2014* 38
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Abbott Laboratories, 2014* 39
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by TCM Biotech International Corp, 2014* 40
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 41
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Phenex Pharmaceuticals AG, 2014* 42
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by GW Pharmaceuticals plc, 2014* 43
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Genextra S.p.a., 2014* 44
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Diabetes and Digestive and Kidney Diseases, 2014* 45
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Tabriz University of Medical Sciences, 2014* 46
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Third Military Medical University, 2014* 47
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Michigan, 2014* 48
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 49
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014* 50
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Diego, 2014* 51
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by FUDAN University, 2014* 52
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Ahvaz Jundishapur University of Medical Sciences, 2014* 53
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Bambino Gesu Hospital and Research Institute, 2014* 54

List of Figures
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Fatty Liver Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Fatty Liver Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Fatty Liver Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Fatty Liver Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Fatty Liver Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Fatty Liver Disease Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, G7 Countries (%), 2014* 15
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, E7 Countries (%), 2014* 18
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Fatty Liver Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Fatty Liver Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Fatty Liver Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Fatty Liver Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Fatty Liver Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Fatty Liver Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
GlobalData Methodology 83

Read the full report:
Fatty Liver Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/617103/Fatty-Liver-Disease-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"We've just seen a huge influx of new partners coming into our ecosystem, and partners building unique offerings on top of our API set," explained Seth Bostock, Chief Executive Officer at IndependenceIT, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Learn how you can use the CoSN SEND II Decision Tree for Education Technology to make sure that your K–12 technology initiatives create a more engaging learning experience that empowers students, teachers, and administrators alike.
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his session at 17th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Partnerships at Com...
SYS-CON Events announced today that VividCortex, the monitoring solution for the modern data system, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The database is the heart of most applications, but it’s also the part that’s hardest to scale, monitor, and optimize even as it’s growing 50% year over year. VividCortex is the first unified suite of database monitoring tools specifically desi...
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...
Digital Transformation is the ultimate goal of cloud computing and related initiatives. The phrase is certainly not a precise one, and as subject to hand-waving and distortion as any high-falutin' terminology in the world of information technology. Yet it is an excellent choice of words to describe what enterprise IT—and by extension, organizations in general—should be working to achieve. Digital Transformation means: handling all the data types being found and created in the organizat...
Chuck Piluso presented a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. Prior to Secure Infrastructure and Services, Mr. Piluso founded North American Telecommunication Corporation, a facilities-based Competitive Local Exchange Carrier licensed by the Public Service Commission in 10 states, serving as the company's chairman and president from 1997 to 2000. Between 1990 and 1997, Mr. Piluso served as chairman & founder of International Te...